个人中心 - 老虎社区

nala

IP属地：北京

帖子 · 5帖子 · 5
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- nalanala
  ·2020-05-11
  这都能被你发现....
  瑞德西韦抗新冠病毒3期临床试验又在我国“悄悄上线”
  《科创板日报》11日讯，《科创板日报》记者从中国生物技术发展中心官网获悉，其于5月8日公示的一组“中国人类遗传资源国际合作临床试验备案情况”中包含了吉利德科学申请的“一项比较性评估瑞德西韦GS-573
  瑞德西韦抗新冠病毒3期临床试验又在我国“悄悄上线”
  1,364 评论
  点赞
  分享
  举报
- nalanala
  ·2020-04-30
  帮你转$吉利德科学(GILD)$
  非常抱歉，此主贴已删除
  1,678 评论
  点赞
  分享
  举报
- nalanala
  ·2020-03-09
  $吉利德科学(GILD)$想卖GILD没卖成的，也许是好事....是好是坏还不一定，早点睡了，网络拥堵不凑热闹了…
  2,227 1
  点赞
  分享
  举报
- nalanala
  ·2020-03-06
  $京东(JD)$dqds
  931 评论
  点赞
  分享
  举报
- nalanala
  ·2020-02-27
  $吉利德科学(GILD)$盘后要上80么？
  3,153 1
  5
  分享
  举报
暂无关注

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3472812625422863","uuid":"3472812625422863","gmtCreate":1509719414616,"gmtModify":1509780099759,"name":"nala","pinyin":"nala","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":53,"tweetSize":5,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":3,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.33%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":950906580,"gmtCreate":1589191507740,"gmtModify":1704179421590,"author":{"id":"3472812625422863","authorId":"3472812625422863","name":"nala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3472812625422863","authorIdStr":"3472812625422863"},"themes":[],"htmlText":"这都能被你发现....","listText":"这都能被你发现....","text":"这都能被你发现....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/950906580","repostId":"1159631648","repostType":2,"repost":{"id":"1159631648","pubTimestamp":1589187562,"share":"https://www.laohu8.com/m/news/1159631648?lang=&edition=full","pubTime":"2020-05-11 16:59","market":"us","language":"zh","title":"瑞德西韦抗新冠病毒3期临床试验又在我国“悄悄上线”","url":"https://stock-news.laohu8.com/highlight/detail?id=1159631648","media":"科创板日报","summary":"《科创板日报》11日讯，《科创板日报》记者从中国生物技术发展中心官网获悉，其于5月8日公示的一组“中国人类遗传资源国际合作临床试验备案情况”中包含了吉利德科学申请的“一项比较性评估瑞德西韦GS-573","content":"<p><span>《科创板日报》11日讯，《科创板日报》记者从中国生物技术发展中心官网获悉，其于5月8日公示的一组“中国人类遗传资源国际合作临床试验备案情况”中包含了<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>申请的“一项比较性评估瑞德西韦GS-5734™ 与标准护理治疗用于治疗中度 COVID-19研究参与者的安全性和抗病毒活性的随机化3期研究”，医疗机构（组长单位）为广州医科大学附属第一医院，CRO为北京法马苏提克咨询有限公司。</span></p>\n<p><img src=\"https://static.tigerbbs.com/3da3ee46827140ec0d5861ff8a7adee3\" tg-width=\"1141\" tg-height=\"169\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞德西韦抗新冠病毒3期临床试验又在我国“悄悄上线”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞德西韦抗新冠病毒3期临床试验又在我国“悄悄上线”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-05-11 16:59 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.chinastarmarket.cn/detail/494768><strong>科创板日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>《科创板日报》11日讯，《科创板日报》记者从中国生物技术发展中心官网获悉，其于5月8日公示的一组“中国人类遗传资源国际合作临床试验备案情况”中包含了吉利德科学申请的“一项比较性评估瑞德西韦GS-5734™ 与标准护理治疗用于治疗中度 COVID-19研究参与者的安全性和抗病毒活性的随机化3期研究”，医疗机构（组长单位）为广州医科大学附属第一医院，CRO为北京法马苏提克咨询有限公司。</p>\n\n<a href=\"https://www.chinastarmarket.cn/detail/494768\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.chinastarmarket.cn/detail/494768","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159631648","content_text":"《科创板日报》11日讯，《科创板日报》记者从中国生物技术发展中心官网获悉，其于5月8日公示的一组“中国人类遗传资源国际合作临床试验备案情况”中包含了吉利德科学申请的“一项比较性评估瑞德西韦GS-5734™ 与标准护理治疗用于治疗中度 COVID-19研究参与者的安全性和抗病毒活性的随机化3期研究”，医疗机构（组长单位）为广州医科大学附属第一医院，CRO为北京法马苏提克咨询有限公司。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":924322974,"gmtCreate":1588233684498,"gmtModify":1704367020400,"author":{"id":"3472812625422863","authorId":"3472812625422863","name":"nala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3472812625422863","authorIdStr":"3472812625422863"},"themes":[],"htmlText":"帮你转<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>","listText":"帮你转<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>","text":"帮你转$吉利德科学(GILD)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924322974","repostId":"922500351","repostType":1,"isVote":1,"tweetType":1,"viewCount":1678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":981526638,"gmtCreate":1583766787824,"gmtModify":1704350868035,"author":{"id":"3472812625422863","authorId":"3472812625422863","name":"nala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3472812625422863","authorIdStr":"3472812625422863"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>想卖GILD没卖成的，也许是好事....是好是坏还不一定，早点睡了，网络拥堵不凑热闹了…","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>想卖GILD没卖成的，也许是好事....是好是坏还不一定，早点睡了，网络拥堵不凑热闹了…","text":"$吉利德科学(GILD)$想卖GILD没卖成的，也许是好事....是好是坏还不一定，早点睡了，网络拥堵不凑热闹了…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/981526638","isVote":1,"tweetType":1,"viewCount":2227,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527816921953472","authorId":"3527816921953472","name":"吉米特","avatar":"https://static.tigerbbs.com/3fcf92e97f5d375411dd881b4f1af97c","crmLevel":5,"crmLevelSwitch":0,"idStr":"3527816921953472","authorIdStr":"3527816921953472"},"content":"收到客服信息，尊敬的用户您好，目前大量交易请求造成上游交易系统超载，使得部分用户提交订单后可能出现“待递交”状态。对此，我们研发团队正在全力紧急处理，请您耐心等待并及时关注订单状态的变化。非常抱歉给您带来不便。","text":"收到客服信息，尊敬的用户您好，目前大量交易请求造成上游交易系统超载，使得部分用户提交订单后可能出现“待递交”状态。对此，我们研发团队正在全力紧急处理，请您耐心等待并及时关注订单状态的变化。非常抱歉给您带来不便。","html":"收到客服信息，尊敬的用户您好，目前大量交易请求造成上游交易系统超载，使得部分用户提交订单后可能出现“待递交”状态。对此，我们研发团队正在全力紧急处理，请您耐心等待并及时关注订单状态的变化。非常抱歉给您带来不便。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":981366690,"gmtCreate":1583509899110,"gmtModify":1704350162957,"author":{"id":"3472812625422863","authorId":"3472812625422863","name":"nala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3472812625422863","authorIdStr":"3472812625422863"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JD\">$京东(JD)$</a>dqds","listText":"<a href=\"https://laohu8.com/S/JD\">$京东(JD)$</a>dqds","text":"$京东(JD)$dqds","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/981366690","isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":989150549,"gmtCreate":1582761924081,"gmtModify":1704347600699,"author":{"id":"3472812625422863","authorId":"3472812625422863","name":"nala","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3472812625422863","authorIdStr":"3472812625422863"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>盘后要上80么？","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>盘后要上80么？","text":"$吉利德科学(GILD)$盘后要上80么？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/989150549","isVote":1,"tweetType":1,"viewCount":3153,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}